.JPG)
Selected companies will receive long-term investments
Bayer takes another step forward and reaffirms its commitment to innovation in healthcare and expands its collaboration with startups around the world. The company has just launched the G4A Partnerships 2019, a competition between startups to receive long-term investments and support from Bayer in the development of their ideas. The company's objective is to find projects in the areas of digital health, digital therapies, artificial intelligence for drug discovery and patient relationship platforms.
Entrepreneurs interested in participating in the G4A Partnerships 2019 have until the may 31st to submit your projects through the website: www.g4a.health.
The proposed challenges are in the areas of women's health, cardiovascular, digital therapies, global health, neurotechnology, oncology, ophthalmology, lung diseases and radiology. The most appropriate approaches will be developed in collaborative teams with Bayer. Cooperation will be supported by a letter of intent. In the new model, startups will receive seed funding of 50,000 to 100,000 euros, plus additional payments when jointly defined objectives are achieved.
“The digital health ecosystem has matured over the years and there are already very well-developed startups across the value chain. Our idea was to simplify the process so that entrepreneurs could work with Bayer and, together, create innovative solutions more quickly. And that's why we created this new way to take our collaboration to the next level," says Eugene Borukhovich, global director of digital health at Bayer.
"For us, it's all about developing new healthcare solutions that can change the healthcare experience," says Dr. Zsuzsanna Varga, who leads the G4A Partnerships 2019. "We are convinced that long-term collaborations with digital healthcare companies sharing the same passion and vision are the best way to achieve this."
Entrepreneurs interested in participating in the G4A Partnerships 2019 have until the may 31st to submit your projects through the website: www.g4a.health.
The proposed challenges are in the areas of women's health, cardiovascular, digital therapies, global health, neurotechnology, oncology, ophthalmology, lung diseases and radiology. The most appropriate approaches will be developed in collaborative teams with Bayer. Cooperation will be supported by a letter of intent. In the new model, startups will receive seed funding of 50,000 to 100,000 euros, plus additional payments when jointly defined objectives are achieved.
“The digital health ecosystem has matured over the years and there are already very well-developed startups across the value chain. Our idea was to simplify the process so that entrepreneurs could work with Bayer and, together, create innovative solutions more quickly. And that's why we created this new way to take our collaboration to the next level," says Eugene Borukhovich, global director of digital health at Bayer.
"For us, it's all about developing new healthcare solutions that can change the healthcare experience," says Dr. Zsuzsanna Varga, who leads the G4A Partnerships 2019. "We are convinced that long-term collaborations with digital healthcare companies sharing the same passion and vision are the best way to achieve this."
EN 
PT 
